Tocqueville Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Tocqueville Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-470	Closed	-$26K	–	1455
2013 Q4	$26K	Sell	470 -5,850	-93%	-$329K	﹤0.01%	1122
2013 Q3	$387K	Sell	6,320 -3,740	-37%	-$253K	﹤0.01%	706
2013 Q2	$588K	Buy	+10,060	New	+$619K	0.01%	597

Other funds holding OREX

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tocqueville Asset Management's OREX Position: Q1 2014 in Review

Tocqueville Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2014, closing a stake of 470 shares — an estimated $26K sold.

Tocqueville Asset Management first reported a position in OREX in Q2 2013 and held it in 3 quarters. The position peaked at $588K in Q2 2013. 129 funds tracked by Wall St. Rank hold OREX as of Q1 2014.

Tocqueville Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
Tocqueville Asset Management sold 470 Orexigen Therapeutics, Inc. shares in Q1 2014, an estimated $26K.
Tocqueville Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
Tocqueville Asset Management's Orexigen Therapeutics, Inc. position peaked at $588K in Q2 2013.
129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2014.

Based on Tocqueville Asset Management's 13F filing for Q1 2014, filed 30 Apr 2014.